ALLERGAN Trademark

Trademark Overview


On Wednesday, January 3, 2018, a trademark application was filed for ALLERGAN with the United States Patent and Trademark Office. The USPTO has given the ALLERGAN trademark a serial number of 87742107. The federal status of this trademark filing is REGISTERED as of Tuesday, July 13, 2021. This trademark is owned by Allergan Sales, LLC. The ALLERGAN trademark is filed in the Pharmaceutical Products and Medical Instrument Products categories with the following description:

House mark used for a line of pharmaceuticals used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma and decongestant formulations, and pharmaceutical preparations to treat and prevent glaucoma; ocular wetting solutions, namely, eye drops, artificial tears and gels for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Oral, transdermal, injectable and intravaginal contraceptive preparatio...

House mark used for a line of surgical, medical, dental and veterinary apparatus and instruments, namely, diagnostic test kits principally composed of medical diagnostic meters that measure conditions of the cardio-vascular and immune systems; intra-uterine non-chemical contraceptive devices; medical diagnostic instruments for the analysis of body fluids; medical devices for treating glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for use in facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics and ophthalmic related diseases and disorders
allergan

General Information


Serial Number87742107
Word MarkALLERGAN
Filing DateWednesday, January 3, 2018
Status700 - REGISTERED
Status DateTuesday, July 13, 2021
Registration Number6420206
Registration DateTuesday, July 13, 2021
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 17, 2018

Trademark Statements


Goods and ServicesHouse mark used for a line of pharmaceuticals used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma and decongestant formulations, and pharmaceutical preparations to treat and prevent glaucoma; ocular wetting solutions, namely, eye drops, artificial tears and gels for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting sensory organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting the central nervous system; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting urogenital organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular disease and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, central nervous system disorders, neurological disorders, neurodegenerative disorders, and depression, neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body; medicated cosmetic skin care preparations
Goods and ServicesHouse mark used for a line of surgical, medical, dental and veterinary apparatus and instruments, namely, diagnostic test kits principally composed of medical diagnostic meters that measure conditions of the cardio-vascular and immune systems; intra-uterine non-chemical contraceptive devices; medical diagnostic instruments for the analysis of body fluids; medical devices for treating glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for use in facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics and ophthalmic related diseases and disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, January 18, 2018
Primary Code005
First Use Anywhere DateFriday, June 30, 2017
First Use In Commerce DateFriday, June 30, 2017

International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status Code6 - Active
Class Status DateThursday, January 18, 2018
Primary Code010
First Use Anywhere DateFriday, June 30, 2017
First Use In Commerce DateFriday, June 30, 2017

Trademark Owner History


Party NameAllergan Sales, LLC
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressMadison, NJ 07940

Party NameAllergan Sales, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressMadison, NJ 07940

Party NameAllergan Sales, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressMadison, NJ 07940

Trademark Events


Event DateEvent Description
Tuesday, July 13, 2021REGISTERED-PRINCIPAL REGISTER
Wednesday, June 9, 2021NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, June 8, 2021ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Monday, June 7, 2021STATEMENT OF USE PROCESSING COMPLETE
Friday, June 4, 2021USE AMENDMENT FILED
Friday, June 4, 2021TEAS STATEMENT OF USE RECEIVED
Wednesday, December 30, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, December 29, 2020EXTENSION 5 GRANTED
Thursday, December 10, 2020EXTENSION 5 FILED
Tuesday, December 29, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, December 10, 2020TEAS EXTENSION RECEIVED
Tuesday, June 16, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, June 12, 2020EXTENSION 4 GRANTED
Friday, June 12, 2020EXTENSION 4 FILED
Friday, June 12, 2020TEAS EXTENSION RECEIVED
Tuesday, December 10, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, December 6, 2019EXTENSION 3 GRANTED
Friday, December 6, 2019EXTENSION 3 FILED
Friday, December 6, 2019TEAS EXTENSION RECEIVED
Friday, June 14, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 12, 2019EXTENSION 2 GRANTED
Wednesday, June 12, 2019EXTENSION 2 FILED
Wednesday, June 12, 2019TEAS EXTENSION RECEIVED
Thursday, November 29, 2018TEAS CHANGE OF CORRESPONDENCE RECEIVED
Saturday, December 1, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 29, 2018EXTENSION 1 GRANTED
Thursday, November 29, 2018EXTENSION 1 FILED
Thursday, November 29, 2018TEAS EXTENSION RECEIVED
Tuesday, June 12, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 17, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 17, 2018PUBLISHED FOR OPPOSITION
Wednesday, March 28, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, March 14, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, March 13, 2018ASSIGNED TO EXAMINER
Thursday, January 18, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, January 6, 2018NEW APPLICATION ENTERED IN TRAM